HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT02728778

Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD)

This study is completed. It focuses on personality disorders and currently lists study information in Germany.

Personality disorders, Borderline personalityDrugFrom 18 Years to 40 Years
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 40 years.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: September 1, 2016
Recruitment status
Completed
Enrollment listed in the registry
54
Sponsor
Hannover Medical School
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug, PROCEDURE
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Germany
Age range
From 18 Years to 40 Years
Official registry ID
NCT02728778
Official title
Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD)

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT02728778. We help you review the study, but cannot decide medical eligibility.

Recruitment & locations

Completed

Hanover, Germany · Hamburg, Germany

Compensation and expense reimbursement have not been verified for this summary.

Checked Official study record (opens in a new tab)
Registry details
Registry conditions (original wording)

Borderline Personality Disorder

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Hannover Medical School.

Does this study involve medication?

Yes. The study involves medication, including incobotulinumtoxin A.

Who can participate?

Listed age limits: 18 years to 40 years.

Is this study still recruiting?

The registry lists this study as completed.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.

Drug study icon
CompletedEUCTR 2020-003469-20

A double blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population (PORTICO)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.